{
    "clinical_study": {
        "@rank": "161495", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: No prior preterm birth & normal cervix length", 
                "description": "Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups."
            }, 
            {
                "arm_group_label": "Group 2: No prior preterm birth & short cervix length", 
                "description": "Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment."
            }, 
            {
                "arm_group_label": "Group 3: Prior preterm birth, normal cervix length, 17-OHPC", 
                "description": "Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment."
            }, 
            {
                "arm_group_label": "Group 4: Prior preterm birth, normal cervix length, no treat", 
                "description": "Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3."
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood for DNA extraction, hormone, and metabolomic analyses\n\n      Cervicovaginal fluid for proteome, cytokines, and matrix metalloproteins (MMPs)"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to analyze how the body handles and responds to progesterone\n      treatment in parous and nulliparous women at risk of pre-term birth."
        }, 
        "brief_title": "The Impact of Vaginal and IM Progestins on the Cervix", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Preterm Birth", 
            "Short Cervical Length"
        ], 
        "condition_browse": {
            "mesh_term": "Premature Birth"
        }, 
        "detailed_description": {
            "textblock": "17-hydroxyprogesterone caproate (17-OHPC) has recently been shown to reduce the rate of\n      recurrent preterm birth while intravaginal progesterone has been shown to reduce the rate of\n      preterm birth in women with short cervix. While these interventions have reduced the rate of\n      preterm birth, the mechanisms of action of these medications are unknown. The objective of\n      this study is to collect and analyze blood and cervicovaginal fluids from pregnant women\n      receiving these medications or other interventions such as  cerclage, pessary, NSAIDs, and\n      combinations thereof.  The goal of the analyses is to assess the impact of these\n      interventions on the cervical proteome, cervical cytokines and cervical structure and to\n      identify potential biomarkers of response and non-response thus providing insights into the\n      mechanisms of action of these drugs."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        All Groups\n\n          -  Singleton gestation (16 0/7 - 23 6/7 weeks gestation)\n\n          -  Willing to provide informed consent\n\n          -  Age 18 - 50 years inclusive\n\n        Additionally,\n\n        Group 1: One or more prior term births (>37 0/7 weeks); No prior spontaneous birth at 16\n        0/7 - 36 6/7 weeks;  and normal cervical length (>25 mm)\n\n        Group 2: Cervical length of 20 mm or less at 16 0/7 - 23 6/7 weeks\n\n        Groups 3 and 4: History of prior spontaneous birth at 16 0/7 - 34 0/7 weeks and normal\n        cervical length (> 25mm) at enrollment.\n\n        Exclusion Criteria\n\n        All Groups\n\n          -  Active labor\n\n          -  Active bleeding\n\n          -  On progestin therapy, chronic steroid, or current NSAID therapy\n\n          -  Actively receiving study treatment in another clinical trial (observational trials\n             allowed)\n\n          -  Major fetal malformation lethal anomalies, or anomalies that may lead to early\n             delivery or increased risk of neonatal death e.g., gastroschisis, spina bifida, or\n             serious karyotypic abnormalities\n\n          -  Amniotic membranes prolapsed beyond the external os (ostium of uterus) or protruding\n             into the vagina\n\n          -  Pregnancy without a viable fetus\n\n          -  Prenatal care or delivery planned elsewhere (unless the study visits can be made as\n             scheduled and complete outcome information can be obtained)\n\n        Additionally:\n\n        Group 1: Cervical dilation greater than or equal to 3cm\n\n        Group 2: Prior preterm birth (16 0/7 - 34 0/7); active deep vein thrombosis, pulmonary\n        embolism, or history of these conditions; known liver dysfunction or disease (active\n        hepatitis, HIV)\n\n        Group 3: inability or unwillingness to use a 17-OHPC compounded product similar in\n        composition to the FDA-approved product; allergy to 17-OHPC or its components\n\n        Groups 1, 3, and 4: cerclage in place or anticipated; congenital mullerian abnormality of\n        the uterus; positive for bacterial vaginosis, chlamydia, gonorrhea, or trichomonas\n\n        Groups 3 and 4: current or history of thrombosis or thromboembolic disorders; known or\n        suspected breast cancer, other hormone-sensitive cancer, or history of these conditions;\n        undiagnosed abnormal vaginal bleeding unrelated to pregnancy; cholestatic jaundice of\n        pregnancy, liver tumors, benign or malignant, or active liver disease; uncontrolled\n        hypertension"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This study consists of 4 groups of women who are between 16  0/7 - 23 6/7 weeks gestation.\n        The allocation of a subject to a group is based on two objective assessments (history of\n        preterm birth and cervical length) and the joint clinical decision of the woman and her\n        physician regarding treatment options.\n\n        Study participants who have no prior preterm births and a normal cervical length will be\n        assigned to Group 1. If the participant has no prior preterm births and a short cervical\n        length, she will be assigned to Group 2 regardless of treatment or no treatment. Group\n        assignment for women with a prior preterm birth and normal cervical length is based on\n        17-OHPC use. Participants who elect to use 17-OHPC will be assigned to Group 3 and those\n        who choose not to receive any treatment will be assigned to Group 4."
            }
        }, 
        "enrollment": {
            "#text": "175", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954095", 
            "org_study_id": "OPRU Progestin"
        }, 
        "intervention_browse": {
            "mesh_term": "Progestins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "17-OHPC, Prometrium, Cerclage, Pre-term birth, Short cervix", 
        "lastchanged_date": "March 19, 2014", 
        "link": {
            "description": "Link is for OPRU homepage", 
            "url": "http://opru.rti.org/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "dflockha@iupui.edu", 
                    "last_name": "David Flockhart, MD, PhD", 
                    "phone": "317-630-8795"
                }, 
                "contact_backup": {
                    "email": "dahaas@iupui.edu", 
                    "last_name": "David Haas, MD, MS", 
                    "phone": "317-630-7837"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "David Flockhart, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scaritis@mail.magee.edu", 
                    "last_name": "Steve Caritis, MD", 
                    "phone": "412-641-4874"
                }, 
                "contact_backup": {
                    "email": "rv@pitt.edu", 
                    "last_name": "Raman Venkataramanan, PhD", 
                    "phone": "412-648-8547"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": {
                    "last_name": "Steve Caritis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ghankins@utmb.edu", 
                    "last_name": "Gary Hankins, MD", 
                    "phone": "409-772-1957"
                }, 
                "contact_backup": {
                    "email": "shclark@utmb.edu", 
                    "last_name": "Shannon Clark, MD, MMS", 
                    "phone": "409-772-1571"
                }, 
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "University of Texas Medical Branch"
                }, 
                "investigator": {
                    "last_name": "Gary D. Hankins, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mhebert@u.washington.edu", 
                    "last_name": "Mary F Hebert, PharmD, FCCP", 
                    "phone": "206-616-5016"
                }, 
                "contact_backup": {
                    "email": "easter@u.washington.edu", 
                    "last_name": "Thomas Easterling, MD", 
                    "phone": "206-543-1521"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98195"
                    }, 
                    "name": "University of Washington"
                }, 
                "investigator": {
                    "last_name": "Mary F Hebert, PharmD, FCCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Determining the Pharmacodynamic Impact of Vaginal and IM Progestins on the Cervix", 
        "overall_contact": {
            "email": "scaritis@mail.magee.edu", 
            "last_name": "Steve Caritis, MD", 
            "phone": "(412) 641-4874"
        }, 
        "overall_contact_backup": {
            "email": "lindabrown@rti.org", 
            "last_name": "Linda M Brown, MPH, DrPH", 
            "phone": "301-816-4626"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Washington", 
                "last_name": "Mary F Hebert, PharmD, FCCP", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Pittsburgh", 
                "last_name": "Steve Caritis, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Texas", 
                "last_name": "Gary Hankins, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Indiana University School of Medicine", 
                "last_name": "David Flockhart, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proteins in the cervicovaginal fluid with expression changes two-fold or greater between day 0 and week 2 of either vaginal or IM progestin therapy.", 
            "measure": "Biomarkers", 
            "safety_issue": "No", 
            "time_frame": "2 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in cervical sonographic gray scale density/length from weeks 0-2, 0-4, and 0-8 after the start of progestin therapy.", 
                "measure": "Cervical sonographic changes", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Proteins in the cervicovaginal fluid whose expression changes significantly from weeks 0-4 and 0-8 after the start of progestin therapy.", 
                "measure": "Protein Expression", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Changes in cervical cytokine inflammatory ratio weeks 0-2, 0-4, and 0-8  after the start of progestin therapy.", 
                "measure": "Cervical cytokines", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Changes in individual cytokines (IL-1\u03b1, IL-1\u03b2, IL-1RA, IL-4, IL-6, IL-8, IL-10, IL-13, and TNF-\u03b1) from weeks 0-2, 0-4, and 0-8 after the start of progestin therapy.", 
                "measure": "Individual cytokines", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Changes in cervical MMPs 1, 2, 8 and 9 from weeks 0-2, 0-4, and 0-8 after the start of progestin therapy.", 
                "measure": "Cervical MMPs", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Test for association between single nucleotide polymorphisms (SNPs) in progestin and estrogen-related candidate genes and changes in the CVF proteome and cervical density and length.", 
                "measure": "Single nucleotide polymorphisms", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }, 
            {
                "description": "Proteins in the cervicovaginal fluid with expression changes two-fold or greater between weeks 0-4 and 0-8 of either vaginal or IM progestin therapy.", 
                "measure": "Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "8 Weeks"
            }
        ], 
        "source": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Pittsburgh", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Indiana University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Texas", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Washington", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "RTI International", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}